RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company’s lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams’ Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.
